Table of Contents Author Guidelines Submit a Manuscript
TheScientificWorldJOURNAL
Volume 9 (2009), Pages 970-981
http://dx.doi.org/10.1100/tsw.2009.103
Review Article

The Nasal Route as a Potential Pathway for Delivery of Erythropoietin in the Treatment of Acute Ischemic Stroke in Humans

National Center for Laboratory Animal Breeding (CENPALAB), Havana, Cuba

Received 29 April 2009; Revised 22 August 2009; Accepted 24 August 2009

Academic Editor: Dirk Hermann

Copyright © 2009 Julio Cesar Garcia-Rodriguez and Iliana Sosa-Teste.

Citations to this Article [29 citations]

The following is the list of published articles that have cited the current article.

  • Dirk M. Hermann, “Enhancing the delivery of erythropoietin and its variants into the ischemic brain,” TheScientificWorldJournal, vol. 9, pp. 967–969, 2009. View at Publisher · View at Google Scholar
  • Murat Digicaylioglu, “Erythropoietin in stroke: Quo vadis,” Expert Opinion on Biological Therapy, vol. 10, no. 6, pp. 937–949, 2010. View at Publisher · View at Google Scholar
  • Derya Sargin, Heidi Friedrichs, Ahmed El-Kordi, and Hannelore Ehrenreich, “Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research,” Best Practice & Research Clinical Anaesthesiology, vol. 24, no. 4, pp. 573–594, 2010. View at Publisher · View at Google Scholar
  • Yamila Rodriguez Cruz, Yuneidys Mengana Tamos, Adriana Munoz Cernuda, Nelvis Subiros Martines, Alina Gonzalez-Quevedo, Iliana Sosa Teste, and Julio Cesar Garcia Rodriguez, “Treatment with Nasal Neuro-EPO Improves the Neurological, Cognitive, and Histological State in a Gerbil Model of Focal Ischemia,” Thescientificworldjournal, vol. 10, pp. 2288–2300, 2010. View at Publisher · View at Google Scholar
  • Dirk M. Hermann, “Nonhematopoietic Variants of Erythropoietin in Ischemic Stroke: Need for Step-Wise Proof-of-Concept Studies,” Thescientificworldjournal, vol. 10, pp. 2285–2287, 2010. View at Publisher · View at Google Scholar
  • Dong-Hyuk Park, David J. Eve, Yong-Gu Chung, and Paul R. Sanberg, “Regenerative Medicine for Neurological Disorders,” Thescientificworldjournal, vol. 10, pp. 470–489, 2010. View at Publisher · View at Google Scholar
  • Xiaoying Zhuang, Xiaoyu Xiang, William Grizzle, Dongmei Sun, Shuangqin Zhang, Robert C Axtell, Songwen Ju, Jiangyao Mu, Lifeng Zhang, Lawrence Steinman, Donald Miller, and Huang-Ge Zhang, “Treatment of Brain Inflammatory Diseases by Delivering Exosome Encapsulated Anti-inflammatory Drugs From the Nasal Region to the Brain,” Molecular Therapy, vol. 19, no. 10, pp. 1769–1779, 2011. View at Publisher · View at Google Scholar
  • Sermin Genc, Zeynep Zadeoglulari, Meryem Gulfem Oner, Kursad Genc, and Murat Digicaylioglu, “Intranasal erythropoietin therapy in nervous system disorders,” Expert Opinion on Drug Delivery, vol. 8, no. 1, pp. 19–32, 2011. View at Publisher · View at Google Scholar
  • Yan Gao, Yuneidis Mengana, Yamila Rodríguez Cruz, Adriana Muñoz, Iliana Sosa Testé, Jorge Daniel García, Yonghong Wu, Julio César García Rodríguez, and Chenggang Zhang, “Different expression patterns of ngb and epor in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of neuro-epo for ischemic insults to the gerbil brain,” Journal of Histochemistry and Cytochemistry, vol. 59, no. 2, pp. 214–227, 2011. View at Publisher · View at Google Scholar
  • David J. Eve, Cesar V. Borlongan, and Paul R. Sanberg, “A Showcase of Bench-to-Bedside Regenerative Medicine at the 2010 ASNTR,” The Scientific World JOURNAL, vol. 11, pp. 1842–1864, 2011. View at Publisher · View at Google Scholar
  • Heiko Sorg, Yves Harder, Christian Krueger, Kerstin Reimers, and Peter M. Vogt, “The Nonhematopoietic Effects of Erythropoietin in Skin Regeneration and Repair: From Basic Research to Clinical Use,” Medicinal Research Reviews, vol. 33, no. 3, pp. 637–664, 2012. View at Publisher · View at Google Scholar
  • Ana Serralheiro, Gilberto Alves, and Amílcar Falcão, “Bioanalysis of small-molecule drugs in nasal and paranasal tissues and secretions: Current status and perspectives,” Central European Journal of Chemistry, vol. 10, no. 3, pp. 686–702, 2012. View at Publisher · View at Google Scholar
  • Kamilla W. Miskowiak, Maj Vinberg, Catherine J. Harmer, Hannelore Ehrenreich, and Lars V. Kessing, “Erythropoietin: A candidate treatment for mood symptoms and memory dysfunction in depression,” Psychopharmacology, vol. 219, no. 3, pp. 687–698, 2012. View at Publisher · View at Google Scholar
  • Jing-yi Zhao, Yang Lu, Shou-ying Du, Xiao Song, Jie Bai, and Yue Wang, “Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations,” Journal of Zhejiang University SCIENCE B, vol. 13, no. 12, pp. 990–996, 2012. View at Publisher · View at Google Scholar
  • Alicia Lagarto, Yamile Vega, Irene Beausoleil, Viviana Bueno, Jose A. Sánchez, Micaela Couret, Odalys Valdés, Pedro Barzaga, Raisell López, Isbel Guerra, and Tatiana Gabilondo, “Short-term intra-nasal erythropoietin administration with low sialic acid content is without toxicity or erythropoietic effects,” Current Neurovascular Research, vol. 9, no. 4, pp. 233–238, 2012. View at Publisher · View at Google Scholar
  • Iliana Sosa Teste, Yuneidys Mengana Tamos, Yamila Rodríguez Cruz, Adriana Muñoz Cernada, Janette Cruz Rodríguez, Nelvis Subirós Martínez, Rosa Maria Coro Antich, Alina González-Quevedo, and Julio Cesar García Rodríguez, “Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil,” The Scientific World Journal, vol. 2012, pp. 1–12, 2012. View at Publisher · View at Google Scholar
  • Claudia Robertson, and Saeed Sadrameli, “Erythropoietin in the Neurology ICU,” Current Treatment Options in Neurology, vol. 15, no. 2, pp. 104–112, 2013. View at Publisher · View at Google Scholar
  • Tangui Maurice, Muhammad-Hariri Mustafa, Catherine Desrumaux, Emeline Keller, Gaelle Naert, Maria de la C. Garcia-Barcelo, Yamila Rodriguez Cruz, and Julio Cesar Garcia Rodriguez, “Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the A beta(25-35) non-transgenic mouse model of Alzheimer's disease,” Journal of Psychopharmacology, vol. 27, no. 11, pp. 1044–1057, 2013. View at Publisher · View at Google Scholar
  • Amalia Merelli, Liliana Czornyj, and Alberto Lazarowski, “Erythropoietin: A neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy,” Current Pharmaceutical Design, vol. 19, no. 38, pp. 6791–6801, 2013. View at Publisher · View at Google Scholar
  • Jun Chen, Guodong Cao, Xiaolei Liu, Anthony Kian-Fong Liou, Zheng Jing, Xunming Ji, Xiangrong Liu, Feng Yan, Ping Liu, Yumin Luo, Juan Xing, and Haiping Zhao, “The neuroprotective mechanism of erythropoietin-tat fusion protein against neurodegeneration from ischemic brain injury,” CNS and Neurological Disorders - Drug Targets, vol. 13, no. 8, pp. 1465–1474, 2014. View at Publisher · View at Google Scholar
  • Ravi Kant Upadhyay, “Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier,” BioMed Research International, vol. 2014, pp. 1–37, 2014. View at Publisher · View at Google Scholar
  • Hong-tao Li, Tian-tuo Zhang, Zhuang-gui Chen, Jin Ye, Hui Liu, Xiao-ling Zou, Yan-hong Wang, and Hai-ling Yang, “Intranasal administration of CpG oligodeoxynucleotides reduces lower airway inflammation in a murine model of combined allergic rhinitis and asthma syndrome,” International Immunopharmacology, vol. 28, no. 1, pp. 390–398, 2015. View at Publisher · View at Google Scholar
  • Federica Marcuzzi, Silvia Zucchelli, Maria Bertuzzi, Claudio Santoro, Gianluca Tell, Piero Carninci, and Stefano Gustincich, “ Isoforms of the Erythropoietin receptor in dopaminergic neurons of the Substantia Nigra ,” Journal of Neurochemistry, 2016. View at Publisher · View at Google Scholar
  • Yamila Rodríguez Cruz, Manon Strehaiano, Teresita Rodríguez Obaya, Julío César García Rodríguez, and Tangui Maurice, “An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer’s Disease,” Journal of Alzheimer's Disease, pp. 1–18, 2016. View at Publisher · View at Google Scholar
  • Oksana Dmytriyeva, Stanislava Pankratova, Irina Korshunova, and Peter S. Walmod, “Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects,” Mediators of Inflammation, vol. 2016, 2016. View at Publisher · View at Google Scholar
  • Orestes Santos-Morales, Alina Díaz-Machado, Daise Jiménez-Rodríguez, Yaisel Pomares-Iturralde, Tatiana Festary-Casanovas, Carlos A. González-Delgado, Sonia Pérez-Rodríguez, Eulalia Alfonso-Muñoz, Carmen Viada-González, Patricia Piedra-Sierra, Idrian García-García, Daniel Amaro-González, Julio César García-Rodríguez, Iliana Sosa-Testé, Alicia Lagarto-Parra, Laura Barrero-Viera, Marlene David-Baldo, Maura Tamayo-Rodríguez, Ivonne Rivero-Vázquez, Gricel González-Gamiz, Alis Martín-Trujillo, Yasmila Rodríguez-Fernández, Ana Alfa Ledo-de la Luz, Maylén Álvarez-Delgado, Ivón Howland-Álvarez, and Yolanda Cruz-Gómez, “Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study,” BMC Neurology, vol. 17, no. 1, 2017. View at Publisher · View at Google Scholar
  • Paolo Sgrò, Massimiliano Sansone, Andrea Sansone, Francesco Romanelli, and Luigi Di Luigi, “Effects of erythropoietin abuse on exercise performance,” The Physician and Sportsmedicine, pp. 1–11, 2017. View at Publisher · View at Google Scholar
  • Garzón Fernando, Rodríguez Yamila, García Cesar, and Rama Ramón, “Neuroprotective Effects of neuroEPO Using an In Vitro Model of Stroke,” Behavioral Sciences, vol. 8, no. 2, pp. 26, 2018. View at Publisher · View at Google Scholar
  • Akiko Tanaka, Tomoyuki Furubayashi, Mari Arai, Daisuke Inoue, Shunsuke Kimura, Akiko Kiriyama, Kosuke Kusamori, Hidemasa Katsumi, Reiko Yutani, Toshiyasu Sakane, and Akira Yamamoto, “Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application,” Molecular Pharmaceutics, 2018. View at Publisher · View at Google Scholar